Perimenopause & Menopause: The Functional Approach

Written by Empire Medical Training Editorial Team

Medically reviewed by Faride Ramos, MD Double Board-Certified, Internal & Functional Medicine; Functional Endocrinology

Updated June 2026 ·11 min read

The menopause transition is one of the most common reasons women arrive in a functional-medicine practice frustrated — tired, moody, not sleeping, gaining weight in the midsection, and told the only options are an antidepressant or a synthetic hormone prescription. The functional lens reframes that. Dr. Faride Ramos teaches that hormones work in a symphony: estrogen, progesterone, and the adrenal hormones are constantly talking to each other, and the menopause transition is best understood as a shift in balance, not simply a deficiency of one hormone.

This guide situates perimenopause and menopause within the broader field of functional endocrinology and is written for clinicians who want an accurate, root-cause overview. It is clinical education, not medical advice, and nothing here is a treatment recommendation, protocol, or substitute for individualized assessment and current prescribing standards.

Perimenopause vs. menopause: two phases, two hormone patterns

The single most useful clinical distinction is that perimenopause and menopause have different hormone patterns, even though their symptoms overlap. Perimenopause is the transition — cycles still occur but become irregular in length and character. Menopause is defined retrospectively, after roughly twelve consecutive months without a menstrual period.

What changes first matters enormously. As Ramos frames it, the menstrual cycle has two halves: a follicular (estrogen-dominant) first phase and a luteal (progesterone-dominant) second phase. In perimenopause, ovulation becomes less reliable, and because progesterone is produced after ovulation, progesterone tends to decline first. Estrogen, by contrast, can remain relatively robust and even erratic for a time. The net effect is a shift toward what the functional literature calls estrogen dominance — not necessarily high estrogen in absolute terms, but estrogen unopposed by adequate progesterone.

That reframes a popular misconception. Many patients (and clinicians) assume the transition is simply “estrogen running out.” In reality, for a meaningful stretch of perimenopause the clinical problem is a loss of the brake — progesterone — rather than a loss of the accelerator. By the time true menopause arrives, estrogen has fallen more substantially, and the picture shifts again. Understanding which phase a woman is in is the difference between guessing and reasoning.

The estrogen–progesterone symphony

Ramos describes estrogen as the accelerator and progesterone as the brake. Estrogen is stimulatory: it builds the endometrial lining, supports vaginal and blood-vessel tissue, acts as an antioxidant in the vasculature, and binds to receptors found throughout the body. Progesterone is the counterweight — it opposes estrogen's proliferative drive, prepares the lining, and is calming. Given at night, progesterone breaks down into a GABA-active metabolite that supports sleep, which is one reason declining progesterone so often shows up as insomnia and restlessness early in perimenopause.

When the two fall out of balance, symptoms follow predictably. A relative estrogen excess can drive irregular or heavy bleeding, breast tenderness, irritability, water retention, and disturbed sleep with hot flashes and night sweats. Progesterone deficiency overlaps heavily with that same list — poor sleep, midsection weight gain, mood changes, dry skin. Because the symptoms overlap, the functional approach does not chase a single number; it asks where the balance has tipped. For a closer look at the progesterone side specifically, see our guide to progesterone and hormone balance.

Symptoms of the transition

The transition's symptoms are wide-ranging because estrogen receptors are distributed almost everywhere. Commonly reported features include:

• Vasomotor symptoms — hot flashes and night sweats, the changes in temperature regulation patients describe most often.
• Sleep disruption — difficulty falling or staying asleep, frequently tied to the early loss of progesterone's calming, GABA-supporting effect.
• Mood changes — irritability, anxiety, low mood, and emotional lability, which conventional care too often treats as primary depression rather than a hormonal shift.
• Genitourinary changes — vaginal dryness and decreased libido as estrogen support for that tissue declines.
• Metabolic shifts — carbohydrate cravings, changes in appetite, and weight gain concentrated in the midsection.

No two women present identically, which is precisely Ramos's point about personalized medicine: patients have their own “fingerprints,” and the goal is to identify their imbalance rather than apply a population template. Many of these complaints — especially the fatigue and sleep problems — also overlap with stress physiology, which is why the transition is rarely a hormones-only story. We explore that overlap in our guide to hormones, fatigue, and sleep.

What FSH tells you — and what it doesn't

The classic teaching is that menopause is confirmed by an elevation in FSH (follicle-stimulating hormone). The physiology is real: as the ovaries become less responsive, the pituitary pushes harder, and FSH climbs. Ramos cites this directly as the marker conventional medicine reaches for. But she is equally clear that FSH alone is not the whole picture, and clinicians should hold it loosely.

Two caveats matter. First, the decline begins long before FSH moves. Inhibin falls years earlier — as ovulatory cycles become inconsistent, inhibin drops, and only after a sustained decrease does FSH begin to rise. By the time FSH is unequivocally elevated, the hormonal shift has been underway for a long time. Second, during perimenopause FSH fluctuates substantially; a single value can be misleading, and the diagnosis remains fundamentally clinical — built on symptoms, cycle history, and the whole hormonal context.

After the ovaries: why the adrenals matter

One of the most important and under-appreciated points Ramos teaches is what happens to estrogen after the ovaries wind down. Estrogen production does not simply stop — it shifts source. Roughly 95% of post-ovarian estrogen arises through the adrenal pathway: the adrenal glands produce androstenedione, which the aromatase enzyme converts into estrone, the dominant estrogen of the menopausal years. (Notably, that conversion is several times greater in patients carrying more adipose tissue, because fat is an aromatase-rich site — one reason body composition shapes the hormonal picture.)

This single fact reorganizes the clinical approach. If the adrenals are now a primary estrogen factory, then adrenal and stress health become central to the menopause story. The same adrenal axis that supplies androstenedione also governs the cortisol stress response, and the two compete for the same upstream resources. A woman under chronic stress — with a dysregulated stress axis — is asking her adrenals to do two demanding jobs at once. That is why the functional model treats sleep, stress, and nutrition not as soft add-ons but as direct levers on how the transition is experienced.

The functional, lifestyle-first approach

Because the adrenals and the stress axis are so central, the functional model puts lifestyle first — before pharmacology. This is not a consolation prize; it is the foundation that everything else rests on. Ramos's framework for the transition emphasizes the same root-cause levers that govern the stress response:

• Sleep — restorative sleep supports the cortisol rhythm and the progesterone–sleep loop that frays early in perimenopause.
• Stress management — addressing the HPA axis directly, because chronic stress competes with the adrenal estrogen pathway and amplifies symptoms.
• Nutrition — stabilizing blood sugar and reducing the refined-carbohydrate load that itself acts as a physiologic stressor.
• Movement and body composition — because adipose tissue drives aromatase activity, body composition meaningfully shapes the estrogen picture.
• Reducing environmental estrogen exposure — Ramos flags xenoestrogens from plastics, pesticides, and some personal-care products as external contributors to estrogen excess worth educating patients about.

None of this is a substitute for proper diagnosis. The functional approach is a clinician-led method of getting to the root cause, not a do-it-yourself protocol — and it pairs naturally with the systems thinking taught across the broader functional medicine cluster.

Where hormone replacement fits

When lifestyle is in place and symptoms still warrant it, hormone therapy enters the conversation — but as an individualized, prescriber-managed decision, never a default. Ramos's clinical position is nuanced and worth stating plainly: the historical harms attributed to hormone therapy were largely tied to synthetic hormones and combinations that bind and behave differently than the body's own, and she draws a sharp distinction between those and bioidentical hormones matched to what a given woman is actually lacking. That distinction — along with dosing, delivery routes, monitoring, and contraindications — is exactly the territory that belongs to a trained prescriber and individualized testing, not a general educational page.

Because hormone replacement is its own discipline with its own safety and regulatory nuance, we keep the prescribing detail in a dedicated cluster. For the replacement-therapy side — bioidentical options, the synthetic-versus-bioidentical debate, and how therapy is monitored — see Empire's bioidentical hormone replacement therapy resource center. The honest bottom line: HRT decisions are personalized and risk-stratified, FSH alone does not make them, and they require proper work-up, monitoring, and clinician competence.

Safety, scope, and red flags

Hormonal symptoms can mask conditions that demand a different work-up, so the transition is never a license to treat by pattern alone. Abnormal or postmenopausal bleeding requires evaluation rather than assumption. A personal or family history of hormone-sensitive cancers, clotting disorders, or cardiovascular disease changes the risk calculus and the candidacy for hormone therapy. Severe mood symptoms warrant appropriate mental-health assessment. And any hormone or thyroid intervention requires proper baseline testing and ongoing monitoring — hormones are not “set and forget.”

This page is clinician education, not patient self-treatment. The functional-medicine framing — estrogen dominance, the adrenal estrogen pathway, HPA-axis dysregulation — is a way of reasoning about a complex transition, to be applied within proper diagnosis, monitoring, and referral. When red flags appear, the right move is a thorough medical work-up, not a supplement or a hormone.